Company Confidential
PDA Midwest 13th Annual Microbial Control and Contamination
Cleanroom Validation – Disinfection and Environmental Monitoring
September 22, 2021
Joe McCall, SM (NRCM)
Director, QA Technical Services
ADMA Biologics
Company Confidential2
Cleanroom Qualification / Validation
Agenda:
Regulatory Perspectives
Best Practices in
• Environmental Monitoring
• Program Development
• Investigations
3Company Confidential
FDA White Oak Campus
Division of Manufacturing and Product Quality
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research
Regulatory Perspectives
4Company Confidential
Fictional Start-Up Facility – What FDA Investigators should expect to find
Regulatory Perspectives
Inside Info
AGENDA• EM Program Development - Risk Based Approach to Qualification: Site Selection,
Sampling Plan Methods / Frequencies, and Data Handling
– Environmental Qualifications for RABS and Isolators
• EM Data: Understanding the Limits of EM Data w/Special Focus on Excursions and Investigations
5Company Confidential
CFR Part 211 CGMP for Finished Pharmaceuticals
211.42 Buildings and Facilities
• “The flow…shall be designed to prevent contamination.”• Floors, walls, and ceilings of smooth, hard surfaces that are easily cleanable;• (ii) Temperature and humidity controls;• (iii) An air supply filtered through high-efficiency particulate air filters under positive pressure,
regardless of whether flow is laminar or nonlaminar;• (iv) A system for monitoring environmental conditions;• (v) A system for cleaning and disinfecting the room and equipment to produce aseptic
conditions;• 211.46• Equipment for adequate control over air pressure, micro-organisms, dust, humidity, and
temperature…
Regulatory Expectations
6Company Confidential
Guidance and Standards: What should be expected of Cleanroom Manufacturers?
ISO 14644 / 2004 FDA CGMP
ISO 14644 Cleanrooms and Associated Controlled Environments –
• Part 1 (2015): Classification of Air Cleanliness by Particle Concentration
• Part 2 (2015): Monitoring to Provide Evidence of Cleanroom Performance Related to Air Cleanliness by Particle Concentration
• A risk assessment shall be undertaken in order to:
• - develop a monitoring plan by determining the factors that may affect the ability to maintain the agreed air cleanliness by particle concentration of the cleanroom or clean zone
• - determine the monitoring requirements to provide evidence of performance
Regulatory Expectations
7Company Confidential
Industry
No excuse for not knowing
• PDA
• PIC/S
• IEST
• ISPE
• PMF
• BPOG
• ASM
• …
Guidance and Standards: What should be expected of Cleanroom Manufacturers?
Regulatory
• EU Guidelines to CGMP for Medicinal Products Annex 1
• 2004 FDA CGMP Guidance for Industry Sterile Drug Products Produced by Aseptic Processing
• USP <1116> Microbiological Control and Monitoring of Aseptic Processing Environments
8Company Confidential
Annex 1…revision
• 15 pages…to 50
• 127 clauses…to 269
• Mention of “risk” from 20 times…to 92
• References to “Risk Assessment” and “Risk Management” throughout
Regulatory Expectations
“Clean rooms and clean air devices should be routinely monitored in operation and the monitoring locations based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean air devices.”
9Company Confidential
USP <1116> Microbiological Control and Monitoring of Aseptic Processing Environments
“Monitoring locations should be based upon an assessment of risk.”
In case there was any doubt…
10Company Confidential
Historical Current (better!)
• Based on higher risk aseptic processes & opinion, ambiguous selection criteria
• Program tailored to specific facility and processes; criteria based on objective risk-based approaches
Risk based Approach to Site Selection, Sampling Plan Methods / Frequencies & Data
11Company Confidential
Risk Based Approach to: Site Selection, Sampling Plan Methods / Frequencies, & Data
•Cross-functional Group Project: Led by SMEs in Pharmacuetical Microbiology / Contamination Control
• Identify Risk Factors for Process & Area
• In-person Assessment of Risks: Process & Area
EM Program Development
•FMEA / Flow Charts / HACCP / Process Mapping
12Company Confidential
Risk Based Approach to: Site Selection, Sampling Plan Methods / Frequencies, & Data
• Map the Area
• Grid overlay
• Specify Critical Functional Areas
• Suggest defining grid size by ISO classification (5, 7, 8) or Grade (ABCD)
EM Program Development
13Company Confidential
Risk Based Approach to: Site Selection, Sampling Plan Methods / Frequencies, & Data
Map the Area
Grid overlay
Specify Critical Functional Areas
Suggest defining grid size by ISO classification (5, 7, 8) or Grade (ABCD)
EM Program Development
Examples:
• 0.5 m2 Grade A
• 4.0 m2 for B, C, D
or
• Grade A 1m2, Grade B 2m2, Grade C 3m2 and Grade D 4m2
14Company Confidential
Risk Criteria Rationalized Frequency
• Easy to Clean / Sanitize / Disinfect / Sterilize
• Proximity of Open Product or Product-Contact Parts
• Material Flow
• Personnel Presence & Movement
• Interventions: complex, simple, prolonged, routine, non-routine
• Nature & frequency of Interventions, Process Steps
• Based in principles of Risk, Science, & Logic
• 2 Factors most heavily weighed for Frequency
• Probability of Contamination
• Potential for Impact to Product Quality
• Differentiate by Grade
• Differentiate by Function
• High Traffic Areas – Material Pass-Through and Personnel Entryways
• Differentiate Floors, Walls, Ceilings, Equipment, Touch Points
Site Selection / Sampling Plan
15Company Confidential
General Attributes
• Follows a written & approved sampling plan– Traceability
• Performed by qualified / trained samplers
• Defined number of “rounds”
• At-Rest / In-Operation
• Acceptance Criteria– If initial EM qualification, may be informational or target levels
• Response, Resolution, Remediation
Implementation
16Company Confidential
EM Program – Can it demonstrate recovery after a loss of control, planned or unplanned?
Need to have a written plan
FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice (Sept. 2004 Pharmaceutical CGMPs)
• “Deviation or change control systems should address atypical conditions posed by shutdown of air handling systems or other utilities, and the impact of construction activities on facility control. Written procedures should address returning a facility to operating conditions following a shutdown.”
Question:
17Company Confidential
Environmental Qualifications for Isolators
Traditional EM design principles are inappropriate
Far lower or better rates of contamination thantraditional cleanroom
Additional equipment, sampling, etc. in a confined space with exceptional control
Spatial limitations
Non value-added monitoring increases cost & resource consumption
Advanced Aseptic Processing Technology
18Company Confidential
Test Results, Excursions, and Investigations
Principles to Avoid the Over-, Under-, and Mis-interpretation
of EM Data
Understanding the Limits of EM Data
19Company Confidential
Understanding the Limits of EM Data w/Special Focus on Excursions and Investigations
Cultivation-based Sampling
Accuracy at low levels (<25 CFU) is poor
Variability
EM Data Limits
20Company Confidential
The Great Plate Anomaly
Cultivation-Based Microbiology
~100 times more cells than colonies ≈ 99% “unculturable”
• Annu Rev Microbiol. 1985;39:321-46.
• Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats.
• Staley JT, Konopka A
21Company Confidential
LIMITS
0 – 60% Recovery
Dependent on Surface Type
Dependent on Operator Technique
Dependent on…
• Condition of microbe
• Temperature
• Humidity
• Media type
• Exposure time
• Incubation time
etc.
Understand Inherent Variability and Imprecision
22Company Confidential
Relevance of Sampling Method
Don’t overinterpret those 0 CFUs
25 cm2 contact plate in a 10’ x 10’ Room
1 floor plate = 0.03% of surface area
23Company Confidential
“Zero” Significance
Adapted from “Regulation of Aseptic Processing in the 21st Century”, 2011, Pharmaceutical Technology, Akers & Agalloco
Example of over-interpreting “0 CFU” results from EM
• 500 Air Changes per hour
• Cleanroom area of 500 m3
• Total volume of air = 250,000/m3 of air per hour
1,000 instruments each collecting 6 m3/hour could sample 6,000 m3 out of 250,000 m3…
…or just 0.24%
24Company Confidential
Where to Begin?
– Manned cleanrooms and work zones have microbial presence
– Systemic failures should have demonstrable causes
– Deviations from Standard Operating Procedure are risky
– Breach in primary control system(s) is a probable RC
– Involvement of Microbiology• Identification of contaminant(s)• Review of EM and relevant test histories
– Batch Record Review– Training records– Method validation
Investigations
25Company Confidential
Assess Validity of Sample Causes of Bad Investigations
• Sample collection
• Relevant Associated Testing? (warning, pitfall here)
• Sample Transport, Chain of Custody maintained?
• Appropriate Sample Storage Conditions?
• Analyst Qualification, Training, and Experience Level?
• Test Equipment Validated and Calibrated? Good Working Order?
• Assumption is still too pervasive that an aseptic processing environment is sterile, or at least must yield EM data that signifies sterility
• Ascribing qualities to microbial data that it does not possess over and under interpretation of EM data is common
• Seeing “patterns” or “trends” where no meaningful correlation exists
• Pressure to identify palatable RC
Site Selection / Sampling Plan
26Company Confidential
Evaluate Cleaning & Disinfection Program as a potential cause
• Disinfectant application conditions
• Time / Temperature
• Application method
• Personnel – experience, technique
• Water quality
• Extra shift
• New personnel
• Construction
• Chemical agent (conc., product quality)
Site Selection / Sampling Plan
27Company Confidential
Optimized Pitfalls
• Operator interviews
• First-hand observations
• Senior Management Support
• Empowered engaged employees
• Lack of true subject matter experts on staff
• Misapplication of technologies
• Misunderstanding of test methods
• Depth and breadth of staff experience
• Status Quo
EM Investigations
28Company Confidential
Holmes, Ockham & Logical Fallacies
Sherlock Holmes, “…when you have eliminated the impossible, whatever you’re left with, however improbable, is the truth.” The Sign of the Four, ch. 6 (1890), Sherlock Holmes in The Sign of the Four (Doubleday p. 111)
Investigations
William of Ockham, 14th century Franciscan friarNotable for problem-solving principle that states "entities should not be multiplied unnecessarily”Ockham’s Razor or "the law of briefness"
29Company Confidential
Logical Fallacies
AVOID THESE!
Investigations
Appeal to Probability
Post hoc ergo propter hoc
– After this, therefore because of this
Correlation Proves Causation
Cherry picking
Slippery slope
Appeal to Authority
Ad hoc hypothesis
30Company Confidential
Takeaways
Our biopharma company must have a qualified EM program for their facility
Developed and established using principles and tools of Risk Management
Cleanroom operators must understand microbiology and contamination control principles.
All personnel must receive initial and periodic training in aseptic processing, interventions, gowning, contamination control.
This training MUST be delivered by Subject Matter Expert(s), proficient in the topics they teach.
Data and Investigations of microbial contamination issues need to be looked at through different lens.
31
Thank You
Company Confidential